Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of lowdose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. Methods: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. Results: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was −41.3% ± 26.1% (p < 0.001) in the regular-dose group and −21.1% ± 45.1% (p = 0.005) in the low-dose group. In the lowdose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. Conclusions: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria.
Abstract
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of lowdose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day. Methods: Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group. Clinical and laboratory data were collected at baseline, and at 4, 8, 12, and 24 weeks after valsartan therapy. Results: Forty-three patients (low-dose group, n = 23; regular-dose group, n = 20) were enrolled in the study. Proteinuria decreased significantly not only in the regular-dose group but also in the low-dose group. The change in urine protein-to-creatinine ratio at week 24 was −41.3% ± 26.1% (p < 0.001) in the regular-dose group and −21.1% ± 45.1% (p = 0.005) in the low-dose group. In the lowdose group, blood pressure was constant throughout the study period, and there was no symptomatic hypotension. In the regular-dose group, blood pressure decreased at weeks 8 and 12. No significant change in glomerular filtration rate, serum creatinine level, or serum potassium level was observed during the study period. Conclusions: Our results suggest that low-dose valsartan can significantly reduce proteinuria without causing any intolerability in normotensive IgAN patients with minimal proteinuria.
참고문헌 (29)
- Wyatt RJ, "IgA nephropathy", N Engl J Med, 368, pp.2402~2414 (2013)
- Geddes CC, "A tricontinental view of IgA nephropathy", Nephrol Dial Transplant, 18, pp.1541~1548 (2003)
- Reich HN, "Remission of proteinuria improves prognosis in IgA nephropathy", J Am Soc Nephrol, 18, pp.3177~3183 (2007)
- Barbour SJ, "Risk stratification of patients with IgA nephropathy", Am J Kidney Dis, 59, pp.865~873 (2012)
- Coppo R, "Factors predicting progression of IgA nephropathies", J Nephrol, 18, pp.503~512 (2005)
- D’Amico G, "Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome", Semin Nephrol, 24, pp.179~196 (2004)
- Le W, "Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population", Nephrol Dial Transplant, 27, pp.1479~1485 (2012)
- Gutierrez E, "Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria", J Am Soc Nephrol, 23, pp.1753~1760 (2012)
- Donadio JV, "Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy", Nephrol Dial Transplant, 17, pp.1197~1203 (2002)
- Szeto CC, "The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria", Am J Med, 110, pp.434~437 (2001)
- Usui J, "Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features", Intern Med, 40, pp.697~702 (2001)
- "Chapter 10: immunoglobulin A nephropathy", Kidney Int Suppl, 2, pp.209~217 (2011)
- Woo KT, "Beneficial effects of high-dose losartan in IgA nephritis", Clin Nephrol, 71, pp.617~624 (2009)
- Jafar TH, "Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis", Ann Intern Med, 139, pp.244~252 (2003)
- Horita Y, "Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy", Hypertens Res, 27, pp.963~970 (2004)
- Tomino Y, "Antiproteinuric effect of olmesartan in patients with IgA nephropathy", J Nephrol, 22, pp.224~231 (2009)
- Shimizu A, "Lowdose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy", Hypertens Res, 31, pp.1711~1717 (2008)
- Pozzi C, "ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study", J Nephrol, 19, pp.508~514 (2006)
- Working Group of the International IgA Nephropathy Network, "The Oxford classification of IgA nephropathy:rationale, clinicopathological correlations, and classification", Kidney Int, 76, pp.534~545 (2009)
- Li PK, "Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study", Am J Kidney Dis, 47, pp.751~760 (2006)
- Praga M, "Treatment of IgA nephropathy with ACE inhibitors:a randomized and controlled trial", J Am Soc Nephrol, 14, pp.1578~1583 (2003)
- "Treatment and prognosis of IgA nephropathy" (2015)[URL]
- Appel GB, "The IgA nephropathy treatment dilemma", Kidney Int, 69, pp.1939~1944 (2006)
- Shen P, "Clinical course and prognostic factors of clinical early IgA nephropathy", Neth J Med, 66, pp.242~247 (2008)
- Yamamoto R, "Even partial remission of proteinuria is associated with better renal outcome in patients with IgA nephropathy", Nat Clin Pract Nephrol, 4, pp.246~247 (2008)
- Mauer M, "Renal and retinal effects of enalapril and losartan in type 1 diabetes", N Engl J Med, 361, pp.40~51 (2009)
- Bilous R, "Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials", Ann Intern Med, 151, pp.11~20 (2009)
- Han SH, "Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy", Nephrol Dial Transplant, 26, pp.1570~1575 (2011)
- Hotta O, "Regression of IgA nephropathy: a repeat biopsy study", Am J Kidney Dis, 39, pp.493~502 (2002)